Cargando…

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]

The combination of pemetrexed and sorafenib has significant clinical activity against a wide variety of tumor types in patients and the present studies were performed to determine whether sildenafil enhances the killing potential of [pemetrexed + sorafenib]. In multiple genetically diverse lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355112/ https://www.ncbi.nlm.nih.gov/pubmed/28088782 http://dx.doi.org/10.18632/oncotarget.14562

Ejemplares similares

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
por: Booth, Laurence, et al.
Publicado: (2016)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)

Phase I study of pemetrexed with sorafenib in advanced solid tumors
por: Poklepovic, Andrew, et al.
Publicado: (2016)

HDAC inhibitors enhance the immunotherapy response of melanoma cells
por: Booth, Laurence, et al.
Publicado: (2017)

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2016)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2019)

Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43
por: Dent, Paul, et al.
Publicado: (2021)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Kinase inhibitors: look beyond the label on the bottle
por: Dent, Paul, et al.
Publicado: (2019)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
por: Tavallai, Mehrad, et al.
Publicado: (2016)

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
por: Tavallai, Mehrad, et al.
Publicado: (2016)

AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy
por: Dent, Paul, et al.
Publicado: (2022)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
por: Booth, Laurence, et al.
Publicado: (2017)

Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species
por: Roberts, Jane L., et al.
Publicado: (2017)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies
por: Dent, Paul, et al.
Publicado: (2019)

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy
por: Cruickshanks, Nichola, et al.
Publicado: (2013)

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)

AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication
por: Rayner, Jonathan O., et al.
Publicado: (2020)

OSU‐03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood–Brain Barrier: Implications for Anti‐Cancer Therapies
por: Booth, Laurence, et al.
Publicado: (2015)

Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
por: Tavallai, Mehrad, et al.
Publicado: (2015)

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins
por: Booth, Laurence, et al.
Publicado: (2021)

Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations
por: Li, Jing, et al.
Publicado: (2016)

The efficacy of PDE5 inhibitors in diabetic patients
por: Swiecicka, Agnieszka
Publicado: (2022)

PDE5 inhibitor drugs for use in dementia
por: Hainsworth, Atticus H., et al.
Publicado: (2023)

Screening and Determination of Synthetic PDE-5 Inhibitors in Adulterated Sexual Enhancement Supplements
por: Jairoun, Ammar Abdulrahman, et al.
Publicado: (2022)

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
por: Coleman, D. Jackson, et al.
Publicado: (2020)

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
por: Kayık, Gülru, et al.
Publicado: (2017)

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors
por: Kolontarev, Konstantin, et al.
Publicado: (2016)

Treatment Strategy for Non-Responders to PDE5 Inhibitors
por: Park, Nam Cheol, et al.
Publicado: (2013)

AB041. Evolution of PDE5 inhibitors in Korea
por: Moon, Du Geon
Publicado: (2015)

Comparative dissolution study on counterfeit medicines of PDE-5 inhibitors
por: Deconinck, E., et al.
Publicado: (2014)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

GZ17-6.02 kills prostate cancer cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2022)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9p9942vdltbgeu40p4orkbl5fs